VistaGen Therapeutics (VTGN) Expected to Announce Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) will likely be issuing its Q3 2026 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.51) per share and revenue of $0.14 million for the quarter. Investors may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.16 million. On average, analysts expect VistaGen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Stock Performance

VTGN stock opened at $0.53 on Thursday. The stock has a market capitalization of $20.78 million, a P/E ratio of -0.28 and a beta of 0.32. VistaGen Therapeutics has a one year low of $0.51 and a one year high of $5.14. The company has a 50 day moving average price of $1.69 and a two-hundred day moving average price of $2.92.

Key Headlines Impacting VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Neutral Sentiment: Context — VistaGen is a clinical‑stage biopharma focused on neuropsychiatric therapies; the class period cited by filings runs from April 1, 2024 through December 16, 2025. Small market cap and low recent prices can amplify downside moves.
• Negative Sentiment: Class action filed on behalf of VTGN purchasers for the period April 1, 2024–December 16, 2025; Robbins LLP is soliciting claimants and publicizing the suit (raises litigation risk and potential financial/management distraction). VTGN CLASS ACTION ALERT: Robbins LLP Urges Vistagen Therapeutics, Inc. Stockholders to Reach Out for Information About the Securities Class Action Lawsuit
• Negative Sentiment: Multiple investor‑rights firms (Levi & Korsinsky, Rosen, Bragar Eagel & Squire, Gross, Faruqi, Holzer, etc.) have issued notices urging investors to contact counsel and meet a March 16, 2026 lead‑plaintiff deadline — broad media outreach increases awareness and potential participation in the suit. VTGN INVESTOR ALERT — LEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS
• Negative Sentiment: Allegations specifically reference false/misleading statements or failures to disclose risks around the Phase 3 PALISADE‑3 fasedienol trial — if true, this targets core clinical development messaging and could affect investor confidence and potential future fundraising. Lead‑Plaintiff Deadline of March 16, 2026 in the Vistagen Therapeutics, Inc. (VTGN) Securities Class Action Announced by Holzer & Holzer, LLC

Hedge Funds Weigh In On VistaGen Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of VTGN. Two Sigma Investments LP raised its stake in shares of VistaGen Therapeutics by 223.5% during the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after purchasing an additional 199,958 shares during the period. Boothbay Fund Management LLC grew its holdings in VistaGen Therapeutics by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock valued at $699,000 after purchasing an additional 19,166 shares in the last quarter. Jane Street Group LLC acquired a new position in VistaGen Therapeutics in the 2nd quarter worth $190,000. Dimensional Fund Advisors LP lifted its holdings in VistaGen Therapeutics by 56.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock worth $241,000 after buying an additional 24,655 shares in the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new position in VistaGen Therapeutics in the 3rd quarter valued at about $152,000. 78.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VTGN has been the topic of several analyst reports. Jefferies Financial Group restated a “hold” rating and set a $0.90 price objective (down previously from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. William Blair restated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research note on Wednesday, December 17th. Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $0.95.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.